

This form is based on Express Scripts standard criteria and may not be applicable to all patients; certain plans and situations may require additional information beyond what is specifically requested.

Additional forms available: www.express-scripts.com/pa

Fax completed form to **1-877-329-3760**If this an <u>URGENT</u> request, please call 1-800-753-2851

Patient Information	Prescriber Information
Patient First Name:	Prescriber Name:
Patient Last Name:	Prescriber DEA/NPI (required):
	Prescriber Phone #:
Patient ID#:	Prescriber Fax #:
Patient DOB:	Prescriber Address:
Patient Phone #:	State: Zip Code:
Primary Diagnosis:	ICD Code:
Please indicate which drug and strength is being requested: Tazorac 0.05% Topical Cream Tazorac 0.05% Topical Gel Directions for use (i.e. QD, BID, PRN & Qty):	Tazorac 0.1% Topical Cream Tazorac 0.1% Topical Gel
1. What is the indication or diagnosis?	
ichthyosis, autosomal dominant ichthyo Keratosis pilaris (atrophicans) Mycosis fungoides lesions/cutaneous T- Oral lichen planus Plaque psoriasis (psoriasis vulgaris) Psoriasis of fingernails or toenails Acne rosacea Folliculitis Warts Dermatitis or eczema Comedonal acne or cystic acne Skin neoplasms Conditions not listed above (please docu	ument):patient tried one other therapy for the current condition?

	☐ Yes (please indicate)	□ No	☐ Not Applicable	
Are there any othe	er comments, diagnoses	symptoms	, and/or any other information the	a
	mportant to this review?		, and or any other information the	-
	•			
			Date:	
iber Signature:				

Based upon each patient's prescription plan, additional questions may be required to complete the prior authorization process. If you have any questions about the process or required information, please contact our prior authorization team at the number listed on the top of this form.

Prior Authorization of Benefits is not the practice of medicine or a substitute for the independent medical judgment of a treating physician. Only a treating physician can determine what medications are appropriate for the patient. Please refer to the applicable plan for the detailed information regarding benefits, conditions, limitations, and exclusions.

The document(s) accompanying this transmission may contain confidential health information. This information is intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you received this information in error, please notify the sender immediately and arrange for the return or destruction of the documents.

Tazorac: F-14 4.2.2013